P/E ratio for Myriad Genetics (MYGN)
P/E ratio as of May 2024 (TTM): -8.32
According to Myriad Genetics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -8.31908. At the end of 2022 the company had a P/E ratio of -10.4.
P/E ratio history for Myriad Genetics from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -10.4 | -86.01% |
| 2021 | -74.6 | 1062.12% |
| 2020 | -6.42 | -91.51% |
| 2019 | -75.6 | -198.87% |
| 2018 | 76.5 | 320.92% |
| 2017 | 18.2 | -2.97% |
| 2016 | 18.7 | -39.68% |
| 2015 | 31.1 | 36.75% |
| 2014 | 22.7 | 158.67% |
| 2013 | 8.78 | -51.68% |
| 2012 | 18.2 | 7.58% |
| 2011 | 16.9 | 2.77% |
| 2010 | 16.4 | -23.79% |
| 2009 | 21.6 | -29.71% |
| 2008 | 30.7 | -140.31% |
| 2007 | -76.1 | 157.71% |
| 2006 | -29.5 | 64.68% |
| 2005 | -17.9 | 13.91% |
| 2004 | -15.7 | 43.21% |
| 2003 | -11.0 | -29.99% |
| 2002 | -15.7 | -90.75% |
| 2001 | -170 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Abbott Laboratories ABT | 35.0 | -520.97% | 🇺🇸 USA |
 Exact Sciences EXAS | -31.8 | 281.93% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | 99.6 | -1,297.33% | 🇺🇸 USA |
 Biocept
BIOC | -0.0085 | -99.90% | 🇺🇸 USA |
 Bio-Rad Laboratories BIO | -51.4 | 517.53% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.